31 Novel JAK2 inhibitors discovered by Nerviano Medical Sciences featured on the cover of Bioorganic & Medicinal Chemistry Sep 30, 2014
32 Nerviano Medical Sciences' partner Ignyta announces interim data from RXDX-101 phase I clinical trial at 2014 ESMO congress Sep 30, 2014
33 Two young researchers of Nerviano Medical Sciences winners of the award “Premio Società Italiana di Farmacologia- Farmindustria per Ricerche Farmacologiche” 2014 Sep 17, 2014
34 Ignyta and Nerviano announce license agreement for two first-in-class kinase inhibitors Aug 4, 2014
35 Cellectis and Accelera (Nerviano Medical Sciences Group) sign an agreement to complete preclinical studies of Cellectis lead product candidate UCART19 Jun 9, 2014
36 Phase I data of RXDX-101, a kinase inhibitor discovered at Nerviano Medical Sciences, in patients with advanced solid tumors with relevant molecular alterations to be disclosed at 2014 ASCO May 16, 2014
37 Phase II data of Nerviano Medical Science’s kinase inhibitor Milciclib in patients with thymic carcinoma to be reported at 2014 ASCO May 16, 2014
38 NMS scientific publications Mar 26, 2014
39 Nerviano Medical Sciences to present a novel orally available selective small molecule Cdc7 inhibitor at the AACR Annual Meeting 2014 Feb 25, 2014
40 Nerviano Medical Sciences to present data on novel molecules suitable for the generation of novel antibody drug conjugates at the AACR Annual Meeting 2014 Feb 25, 2014

Page 4 of 4

To give you a better browsing experience, NMS Group and Group Companies use own and third part cookies.
Browsing this web site, you allow to use them, according to our  
Cookie Policy.